AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)
Phase 2
Completed
- Conditions
- Rhinitis, Allergic, Seasonal
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 480
- Registration Number
- NCT00807053
- Locations
- 🇺🇸
Altana/Nycomed, Richmond, Virginia, United States
Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 624
- Registration Number
- NCT00805467
- Locations
- 🇷🇴
Research Site, Sibiu, Romania
Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD1446 to Healthy Volunteers
- First Posted Date
- 2008-12-08
- Last Posted Date
- 2009-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 110
- Registration Number
- NCT00803855
- Locations
- 🇸🇪
Research site, Huddinge, Sweden
National Survey on Hypertension
Completed
- Conditions
- Hypertension
- First Posted Date
- 2008-12-08
- Last Posted Date
- 2009-07-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4500
- Registration Number
- NCT00804167
- Locations
- 🇫🇷
Research Site, Zillisheim, France
In-practice Evaluation of Atacand 16mg Antihypertensive Effect
Completed
- Conditions
- Essential Hypertension
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT00802542
- Locations
- 🇱🇻
Research site, Liepaja, Latvia
🇱🇻Research Site, Riga, Latvia
Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes
Completed
- Conditions
- HypertensionType 2 Diabetes
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2009-07-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1060
- Registration Number
- NCT00803660
- Locations
- 🇻🇳
Research Site, Tien Giang, Vietnam
Asthma Control Among Patients Receiving Inhaled Corticosteroids in Thailand
Completed
- Conditions
- Asthma
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1210
- Registration Number
- NCT00800904
- Locations
- 🇹🇭
Research Site, Yasothon, Thailand
Budesonide/Formoterol for Maintenance and Reliever Therapy Among Asthma Patients in Thailand
Completed
- Conditions
- Asthma
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1020
- Registration Number
- NCT00800241
- Locations
- 🇹🇭
Research Site, Trang, Thailand
Effects of Rosuvastatin on Aortic Stenosis Progression
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 378
- Registration Number
- NCT00800800
- Locations
- 🇨🇦
Research site, St. John's, Canada
Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017.
- First Posted Date
- 2008-12-01
- Last Posted Date
- 2009-07-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 56
- Registration Number
- NCT00799747
- Locations
- 🇯🇵
Research Site, Fukuoka, Japan
© Copyright 2025. All Rights Reserved by MedPath